The Committee discusses Amgen’s supplemental New Drug Application (sNDA) 214665/S-005, for LUMAKRAS (sotorasib) tablets for proposed treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer. This supplement proposes to convert the NDA to full approval based on the confirmatory study, CodeBreaK 200. The virtual meeting will be held on October 5 at 9:30 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- Here’s Why Mirati Therapeutics Stock (NASDAQ:MRTX) Soared Yesterday
- Bad news for Amgen could be ‘good’ for Mirati Therapeutics, says Stifel
- FDA staff voice concerns about whether Amgen’s CodeBreaK 200 trial ‘adequate’
- Amgen price target raised to $230 from $210 at Barclays
- FDA Oncologic Drugs Advisory Committee holds virtual meeting